Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Young Adults with Psoriatic Disease at Risk of Early Cardiovascular Disease

Anurag Goel, Joshua Tanzer & Vinit Gilvaz  |  November 7, 2024

Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…

Filed under:ACR ConvergenceConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 PsAArthritis & Rheumatology

Sonelokimab Promising for Patients with PsA

Michele B. Kaufman, PharmD, BCGP  |  October 17, 2024

A phase 2 clinical trial has demonstrated the effectiveness for multiple doses of subcutaneous sonelokimab for the treatment of adults with active psoriatic arthritis.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabnanobodyPsAPsoriatic Arthritissonelokimab

15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions

Michele B. Kaufman, PharmD, BCGP  |  October 17, 2024

Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:EULAREULAR 2024Safetyupadacitinib

Selfie of Dr. Jason Liebowitz attending a lecture during APLAR 2024

A View from Abroad: The ACR Research Exchange Program

Natasha Yetman  |  October 17, 2024

The most recent ACR/APLAR Research Exchange Program gave participants an opportunity to visit Singapore, learn from international research presentations and create connections with colleagues they may never otherwise have met.

Filed under:Career DevelopmentEULAR/OtherMeeting ReportsProfessional Topics Tagged with:APLAR 2024

Type I IFNs in Cutaneous Lupus & Dermatomyositis

Katie Robinson  |  October 14, 2024

Type I interferons (IFNs) play an important role in the immunopathogenesis of cutaneous lupus erythematosus and dermatomyositis skin inflammation, which could potentially be treated with IFN-targeted therapies.

Filed under:ConditionsMyositis Tagged with:Immunologytype I interferon

Meet the Professor: Axial Spondyloarthritis

Keri Losavio  |  October 14, 2024

Axial spondyloarthritis (axSpA) is a complex, immune-mediated inflammatory disorder characterized by inflammatory back pain and axial arthritis. Typical of other diseases in the spondyloarthritis family, the clinical phenotypes can be diverse, and an array of comorbidities often accompanies the spinal disease. “In this Meet the Professor Session at ACR Convergence 2024,” says Christopher Ritchlin, MD,…

Filed under:ACR ConvergenceAxial SpondyloarthritisConditions Tagged with:ACR Convergence 2024ACR Convergence 2024 axSpA

Lupus Update: Findings from the Latest Phase 3 Clinical Trials

Michele B. Kaufman, PharmD, BCGP  |  October 11, 2024

Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.

Filed under:Biologics/DMARDsConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:dapirolizumab pegolEnd-stage renal diseasekidneyLupus nephritisobinutuzumabsystemic lupus erythematosus (SLE)

Interventions to Delay RA Onset

Ruth Jessen Hickman, MD  |  October 9, 2024

Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.

Filed under:ConditionsResearch ReviewsResearch RheumRheumatoid Arthritis Tagged with:preventionRA Resource Center

Insight into the ACR’s Commitment to an Inclusive Committee Composition

Kanika Monga, MD, FACR  |  October 9, 2024

“While our group carefully considered your application, I regret to inform you that you were not selected this year to serve as a committee volunteer.” When the email arrived, gently delivering the news that my application to volunteer with the ACR on a committee had not been accepted, my initial reaction was to dismiss it…

Filed under:From the College Tagged with:ACR standing committeesDiversity

ACR Convergence 2024 Preview: Key Business Takeaways

Carina Stanton  |  October 8, 2024

In sessions in the business of rheumatology track, rheumatology practice leaders will share ways to manage payer complexities head-on while also improving patient care.

Filed under:ACR ConvergencePractice ManagementPractice Support Tagged with:ACR Convergence 2024

  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences